These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2916 related articles for article (PubMed ID: 19102946)

  • 21. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
    Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
    J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
    Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
    Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage chemotherapy in Hodgkin's disease irradiation failures: superiority of doxorubicin-containing regimens over MOPP.
    Santoro A; Viviani S; Villarreal CJ; Bonfante V; Delfino A; Valagussa P; Bonadonna G
    Cancer Treat Rep; 1986 Mar; 70(3):343-8. PubMed ID: 2420444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of preliminary results of involved-field with extended field radiotherapy combined with chemotherapy for early stage Hodgkin's disease].
    Wang WH; Li YX; Song YW; Jin J; Liu YP; Wang SL; Zhou LQ; Liu XF; Yu ZH; Han JZ
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):218-21. PubMed ID: 16875611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hodgkin's disease: summary of twenty years' experience.
    Mazza P; Bocchia M; Zinzani PL; Fiacchini M; Gherlinzoni F; Bandini G; Bendandi M; Frezza GP; Neri S; Barbieri E
    Haematologica; 1992; 77(6):487-93. PubMed ID: 1283856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hodgkin's disease in Indian children: outcome with chemotherapy alone.
    Arya LS; Dinand V; Thavaraj V; Bakhshi S; Dawar R; Rath GK; Singh R; Vats TS
    Pediatr Blood Cancer; 2006 Jan; 46(1):26-34. PubMed ID: 16161019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-protocol.
    Hakvoort-Cammel FG; Buitendijk S; van den Heuvel-Eibrink M; Hählen K
    Pediatr Blood Cancer; 2004 Jul; 43(1):8-16. PubMed ID: 15170884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma.
    Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M;
    Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fifteen-year experience in Hodgkin's disease: role of combined modality treatment and splenectomy in the incidence of secondary acute leukemia.
    Zinzani PL; Fiacchini M; Mazza P; Gherlinzoni F; Bocchia M; Tura S
    Haematologica; 1991; 76(4):305-10. PubMed ID: 1724437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy with alternating MOPP-ABVD in advanced Hodgkin's disease.
    Brusamolino E; Lazzarino M; Morra E; Inverardi D; Merante S; Castelli G; Canevari A; Dornini G; Bernasconi C
    Haematologica; 1989; 74(2):173-9. PubMed ID: 2473013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of favorable early-stage hodgkin's lymphoma treatments: a single-institution review.
    Samant R; Alomary I; Alsaeed E; Al-Jasir B; Bence-Bruckler I; Cross P; Genest P; Huebsch L
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(4):1166-70. PubMed ID: 19695788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of the risk of solid tumor following Hodgkin's disease.
    Maurizi Enrici R; Anselmo AP; Osti MF; Santoro M; Tombolini V; Mandelli F; Biagini C
    Haematologica; 1997; 82(1):57-63. PubMed ID: 9107084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial.
    Eich HT; Diehl V; Görgen H; Pabst T; Markova J; Debus J; Ho A; Dörken B; Rank A; Grosu AL; Wiegel T; Karstens JH; Greil R; Willich N; Schmidberger H; Döhner H; Borchmann P; Müller-Hermelink HK; Müller RP; Engert A
    J Clin Oncol; 2010 Sep; 28(27):4199-206. PubMed ID: 20713848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
    Engert A; Plütschow A; Eich HT; Lohri A; Dörken B; Borchmann P; Berger B; Greil R; Willborn KC; Wilhelm M; Debus J; Eble MJ; Sökler M; Ho A; Rank A; Ganser A; Trümper L; Bokemeyer C; Kirchner H; Schubert J; Král Z; Fuchs M; Müller-Hermelink HK; Müller RP; Diehl V
    N Engl J Med; 2010 Aug; 363(7):640-52. PubMed ID: 20818855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 146.